ClearPoint Neuro Inc.
24.11-2.87 (-10.6%)
Oct 29, 4:00:02 PM EDT · NasdaqCM · CLPT · USD
Key Stats
Market Cap
685.39MP/E (TTM)
-Basic EPS (TTM)
-0.80Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
ClearPoint Neuro posted Q2 revenue of $9.2M, up 17% y/y from $7.9M, fueled by 33% growth in neurosurgery navigation and therapy disposables to $3.4M amid SmartFrame OR and Prism Laser adoption, while biologics and drug delivery added 10% to $4.7M. Gross margin slipped to 60% from 63%, hit by higher inventory reserves, as operating loss widened to $5.7M from $4.7M on R&D and G&A jumps. YTD revenue climbed 14% to $17.7M, with net loss at $11.9M or $0.42 per diluted share across 28.0M shares. Cash swelled to $41.5M after a $28.7M note issuance in May 2025 (8.25%-9.50% rate, maturing 2031) and $3.3M equity raise, though operating cash burn hit $8.7M. Free cash flow not disclosed in the 10-Q. Yet partners hit 60. Regulatory hurdles could stall biologics trials.
8-K
Record Q2 revenue, fresh capital
ClearPoint Neuro posted record Q2 revenue of $9.2 million, up 17% year-over-year, driven by 33% growth in neurosurgery navigation to $3.4 million from SmartFrame and Prism Laser sales. The company secured $33.5 million in financing from Oberland Capital, boosting cash to $41.5 million and fueling its 'Fast. Forward.' expansion into operating rooms and biologics. Yet margins dipped to 60% on inventory reserves. Full-year revenue guidance holds at $36-41 million.
8-K
ClearPoint Neuro expands lab space
ClearPoint Neuro inked a lease on June 16, 2025, for 30,171 square feet in a San Diego life science building, rolling out in phases starting June 13, 2025, and wrapping by July 1, 2026. Base rent kicks off at $5.95 per square foot monthly, with 3% annual bumps and free rent periods up to $2.15M total, while the company shoulders operating expenses from phase one. This expansion bolsters R&D and lab capacity, yet ties up a $179,517 security deposit amid phased buildout risks.
8-K
Annual meeting approvals passed
ClearPoint Neuro's stockholders approved all proposals at the May 21, 2025 annual meeting, electing eight directors including Joseph M. Burnett and Linda M. Liau to serve until 2026. They ratified Cherry Bekaert LLP as auditors for 2025, endorsed executive pay annually, and greenlit amendments to the 2021 Employee Stock Purchase Plan and 2013 Incentive Compensation Plan. This bolsters talent retention amid growth. Directors will revisit frequency in future votes.
8-K
Director pay plan updated
ClearPoint Neuro amended its Non-Employee Director Compensation Plan on May 18, 2025, to boost board retainers and equity grants, aiming to attract top talent. Cash retainers now hit $75,000 for the board chair and $45,000 for others starting July 1, up from $40,000, while committee chairs get $12,000 to $20,000 extra. New and annual directors receive $150,000 in restricted stock units, vesting in a year. This sharpens governance amid talent wars.
IPO
Employees
Sector
Industry
BWAY
Brainsway Ltd.
16.80+0.22
CBLL
CeriBell, Inc.
12.03-0.80
MDT
Medtronic plc.
91.73-1.50
NMTC
NeuroOne Medical Technologies C
0.79-0.03
NPCE
Neuropace, Inc.
10.13-0.49
PEN
Penumbra, Inc.
233.37-2.13
PRCT
PROCEPT BioRobotics Corporation
35.93-1.02
STIM
Neuronetics, Inc.
2.90-0.20
VTAK
Catheter Precision, Inc.
2.44-0.12
VYCO
Vycor Medical, Inc.
0.15+0.00